XClose

UCL Cancer Institute

Menu

Selected publications

  1. Maciocia, P. M., Wawrzyniecka, P. A., Maciocia, N. C., Burley, A., Karpanasamy, T., Devereaux, S., Hoekx, M., O'Connor, D., Leon, T. E., Rapoz-D'Silva, T., Pocock, R., Rahman, S., Gritti, G., Yanez, D. C., Ross, S., Crompton, T., Williams, O., Lee, L. S. H., Pule, M. & Mansour, M. R. Anti-CCR9 Chimeric Antigen Receptor T cells for T Cell Acute Lymphoblastic Leukemia. Blood, doi:10.1182/blood.2021013648 (2022). 

  2. Llombart, V. & Mansour, M. R. Therapeutic targeting of "undruggable" MYC. EBioMedicine 75, 103756, doi:10.1016/j.ebiom.2021.103756 (2022).

  3. Leon, T. E., Rapoz-D'Silva, T., Bertoli, C., Rahman, S., Magnussen, M., Philip, B., Farah, N., Richardson, S. E., Ahrabi, S., Guerra-Assuncao, J. A., Gupta, R., Nacheva, E. P., Henderson, S., Herrero, J., Linch, D. C., de Bruin, R. A. M. & Mansour, M. R. EZH2-Deficient T-cell Acute Lymphoblastic Leukemia Is Sensitized to CHK1 Inhibition through Enhanced Replication Stress. Cancer Discov 10, 998-1017, doi:10.1158/2159-8290.CD-19-0789 (2020).

  4. Rahman, S. & Mansour, M. R. The role of noncoding mutations in blood cancers. Dis Model Mech 12, doi:10.1242/dmm.041988 (2019).

  5. Farah, N., Kirkwood, A. A., Rahman, S., Leon, T., Jenkinson, S., Gale, R. E., Patrick, K., Hancock, J., Samarasinghe, S., Linch, D. C., Moorman, A. V., Goulden, N., Vora, A. & Mansour, M. R. Prognostic impact of the absence of biallelic deletion at the TRG locus for pediatric patients with T-cell acute lymphoblastic leukemia treated on the MRC UKALL2003 trial. Haematologica, doi:10.3324/haematol.2017.185801 (2018).

  6. Mansour, M. R., He, S., Li, Z., Lobbardi, R., Abraham, B. J., Hug, C., Rahman, S., Leon, T. E., Kuang, Y. Y., Zimmerman, M. W., Blonquist, T., Gjini, E., Gutierrez, A., Tang, Q., Garcia-Perez, L., Pike-Overzet, K., Anders, L., Berezovskaya, A., Zhou, Y., Zon, L. I., Neuberg, D., Fielding, A. K., Staal, F. J. T., Langenau, D. M., Sanda, T., Young, R. A. & Look, A. T. JDP2: An oncogenic bZIP transcription factor in T cell acute lymphoblastic leukemia. The Journal of experimental medicine 215, 1929-1945, doi:10.1084/jem.20170484 (2018).

  7. Lobbardi, R., Pinder, J., Martinez-Pastor, B., Theodorou, M., Blackburn, J. S., Abraham, B. J., Namiki, Y., Mansour, M.R., Abdelfattah, N. S., Molodtsov, A., Alexe, G., Toiber, D., de Waard, M., Jain, E., Boukhali, M., Lion, M., Bhere, D., Shah, K., Gutierrez, A., Stegmaier, K., Silverman, L. B., Sadreyev, R. I., Asara, J. M., Oettinger, M. A., Haas, W., Look, A. T., Young, R. A., Mostoslavsky, R., Dellaire, G. & Langenau, D. M. TOX regulates growth, DNA repair, and genomic instability in T-cell Acute Lymphoblastic Leukemia. Cancer Discov, doi:10.1158/2159-8290.CD-17-0267 (2017).
  8. Rahman S, Magnussen M, Leon TE, Farah N, Li Z, Abraham BJ, Alapi KZ, Mitchell RJ, Naughton T, Fielding AK, Pizzey A, Bustraan S, Allen C, Popa T, Pike-Overzet K, Garcia-Perez L, Gale RE, Linch DC, Staal FJ, Young RA, Look AT, Mansour MR. Activation of the LMO2 oncogene through a somatically acquired neomorphic promoter in T-cell acute lymphoblastic leukemia. Blood. 2017 Mar 07. PubMed PMID: 28270453. 
  9. Li Z, Abraham BJ, Berezovskaya A, Farah N, Liu Y, Leon T, Fielding A, Tan SH, Sanda T, Weintraub AS, Li B, Shen S, Zhang J, Mansour MR*, Young RA*, Look AT*. APOBEC signature mutation generates an oncogenic enhancer that drives LMO1 expression in T-ALL. Leukemia. 2017 Mar 28. PubMed PMID: 28260788. (*denotes equal contribution). 
  10. Abraham BJ, Hnisz D, Weintraub AS, Kwiatkowski N, Li CH, Li Z, Weichert-Leahey N, Rahman S, Liu Y, Etchin J, Li B, Shen S, Lee TI, Zhang J, Look AT*, Mansour MR*, Young RA*. Small genomic insertions form enhancers that misregulate oncogenes. Nature communications. 2017 Feb 09;8:14385. PubMed PMID: 28181482.    (*denotes equal contribution). 
  11. Anderson NM, Li D, Peng HL, Laroche FJ, Mansour MR, Gjini E, Aioub M, Helman DJ, Roderick JE, Cheng T, Harrold I, Samaha Y, Meng L, Amsterdam A, Neuberg DS, Denton TT, Sanda T, Kelliher MA, Singh A, Look AT, Feng H. The TCA cycle transferase DLST is important for MYC-mediated leukemogenesis. Leukemia. 2016 Jun;30(6):1365-74. PubMed PMID: 26876595.
  12. Mansour MR, Abraham BJ, Anders L, Berezovskaya A, Gutierrez A, Durbin AD, Etchin J, Lawton L, Sallan SE, Silverman LB, Loh ML, Hunger SP, Sanda T, Young RA, Look AT. Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. Science. 2014 Dec 12;346(6215):1373-7. PubMed PMID: 25394790.  Featured in: Science, Nature Reviews Cancer, Nature Genetics, Cancer Discovery, Faculty of 1000
  13. Mansour MR, Sanda T, Lawton LN, Li X, Kreslavsky T, Novina CD, Brand M, Gutierrez A, Kelliher MA, Jamieson CH, von Boehmer H, Young RA, Look AT. The TAL1 complex targets the FBXW7 tumor suppressor by activating miR-223 in human T cell acute lymphoblastic leukemia. J Exp Med. 2013 Jul 29;210(8):1545-57. PubMed PMID: 23857984.
  14. Mansour MR, Sulis ML, Duke V, Foroni L, Jenkinson S, Koo K, Allen CG, Gale RE, Buck G, Richards S, Paietta E, Rowe JM, Tallman MS, Goldstone AH, Ferrando AA, Linch DC. Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocol. Journal of Clinical Oncology: official journal of the American Society of Clinical Oncology. 2009 Sep 10;27(26):4352-6. PubMed PMID: 19635999.
  15. Howe SJ, Mansour MR, Schwarzwaelder K, Bartholomae C, Hubank M, Kempski H, Brugman MH, Pike-Overzet K, Chatters SJ, de RD, Gilmour KC, Adams S, Thornhill SI, Parsley KL, Staal FJ, Gale RE, Linch DC, Bayford J, Brown L, Quaye M, Kinnon C, Ancliff P, Webb DK, Schmidt M, von KC, Gaspar HB, Thrasher AJ. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest. 2008; 118(9):3143-50.
  16. Gjini E, Mansour MR, Sander JD, Moritz N, Nguyen AT, Kesarsing M, Gans E, He S, Chen S, Ko M, Kuang YY, Yang S, Zhou Y, Rodig S, Zon LI, Joung JK, Rao A, Look AT. A Zebrafish Model of Myelodysplastic Syndrome Produced through tet2 Genomic Editing. Mol Cell Biol. 2015 Mar 1; 35(5):789-804. PubMed PMID: 25512612.
  17. Mansour MR, Reed C, Eisenberg AR, Tseng JC, Twizere JC, Daakour S, Yoda A, Rodig SJ, Tal N, Shochat C, Berezovskaya A, DeAngelo DJ, Sallan SE, Weinstock DM, Izraeli S, Kung AL, Kentsis A, Look AT. Targeting oncogenic interleukin-7 receptor signalling with N-acetylcysteine in T cell acute lymphoblastic leukaemia. Br J Haematol. 2015 Jan;168(2):230-8. PubMed PMID: 25256574.
  18. Li N, Fassl A, Chick J, Inuzuka H, Li X, Mansour MR, Liu L, Wang H, King B, Shaik S, Gutierrez A, Ordureau A, Otto T, Kreslavsky T, Baitsch L, Bury L, Meyer CA, Ke N, Mulry KA, Kluk MJ, Roy M, Kim S, Zhang X, Geng Y, Zagozdzon A, Jenkinson S, Gale RE, Linch DC, Zhao JJ, Mullighan CG, Harper JW, Aster JC, Aifantis I, von Boehmer H, Gygi SP, Wei W, Look AT, Sicinski P. Cyclin C is a haploinsufficient tumour suppressor. Nature Cell Biology. 2014 Nov;16(11):1080-91. PubMed PMID: 25344755.
  19. Shepherd C, Banerjee L, Cheung CW, Mansour MR, Jenkinson S, Gale RE, Khwaja A. PI3K/mTOR inhibition upregulates NOTCH-MYC signalling leading to an impaired cytotoxic response. Leukemia. 2013 Mar;27(3):650-60. PubMed PMID: 23038273.
  20. Lobry C, Oh P, Mansour MR, Look AT, Aifantis I. Notch signaling: switching an oncogene to a tumor suppressor. Blood. 2014 Apr 17;123(16):2451-9. PubMed PMID: 24608975.
  21. Gutierrez A, Grebliunaite R, Feng H, Kozakewich E, Zhu S, Guo F, Payne E, Mansour MR, Dahlberg SE, Neuberg DS, den Hertog J, Prochownik EV, Testa JR, Harris M, Kanki JP, Look AT. Pten mediates Myc oncogene dependence in a conditional zebrafish model of T cell acute lymphoblastic leukemia. J Exp Med. 2011 Aug 1;208(8):1595-603. PubMed PMID: 21727187.

Contact

Dr Marc Mansour…

Dr Marc Mansour
Email: m.mansour@ucl.ac.uk
@Marcrmansour

Mansour Lab

Group members

Further publications